Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05505227 · ClinicalTrials.gov registry record · NA
Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing
A NA study of Opioid-Related Disorders and Buprenorphine, sponsored by Ohio University.
- Active
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT05505227: Active NA study of Opioid-Related Disorders and Buprenorphine, sponsored by Ohio University.
NCT05505227 is a NA study of Opioid-Related Disorders and Buprenorphine that is active but no longer recruiting, run by Ohio University. The registered enrollment target is 400 participants, above the 338-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05505227, a NA study of Opioid-Related Disorders and Buprenorphine, is active but no longer recruiting, sponsored by Ohio University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Buprenorphine is an evidence-based treatment for opioid use disorder that also has strong potential to reduce HIV transmission in people who use drugs. Rural health care professionals are eligible and critically needed to provide these medications, but stigma currently limits provider willingness to prescribe buprenorphine, especially in regions where mortality and HIV transmission secondary to opioid use are high. In this developmental trial, the investigators will adapt, refine, and test the feasibility of a prototype brief stigma-reduction training intervention aimed at increasing buprenorphine prescribing in the rural primary care setting.
Primary Outcome
Feasibility refers to the ease in which a new intervention can be used within a specific setting. It will be measured using the 4-item Feasibility Intervention Measure (FIM). Scale values range from 1 to 5 with higher values indicating a better outcome.
Conditions Studied
Interventions
- BEHAVIORAL Placebo
- BEHAVIORAL Stigma-reduction training
Study Locations (1)
Ohio
- Berkeley Franz - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2025-06-30 |
| Phase | NA |
What the registry record for NCT05505227 still lists
NCT05505227 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 338-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (18% higher).
The record links to 4 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05505227 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05505227 about?
NCT05505227 is a clinical study titled "Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing". Buprenorphine is an evidence-based treatment for opioid use disorder that also has strong potential to reduce HIV transmission in people who use drugs. Rural health care professionals are eligible and critically needed to provide these medications, but stigma currently limits provider willingness to...
What is the current status of trial NCT05505227?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2022-09-01. Estimated completion is 2025-06-30.
What conditions does trial NCT05505227 study?
This clinical trial studies the following conditions: Opioid-Related Disorders, Buprenorphine, Social Stigma, Rural Health Services.
What interventions are being tested in trial NCT05505227?
The interventions under investigation include: Placebo (BEHAVIORAL), Stigma-reduction training (BEHAVIORAL).
Who is sponsoring clinical trial NCT05505227?
This trial is sponsored by Ohio University, which has 51 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05505227 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05505227's enrollment target sits among peer trials
400 8th of 47 higher than 40 of 47 other Opioid-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
RECRUITING · NA
-
Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment
RECRUITING · NA
-
OUD Smartphone Services
ACTIVE NOT RECRUITING · NA
-
Healthy Opioid Prescription Engagement
ACTIVE NOT RECRUITING · NA
-
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
ACTIVE NOT RECRUITING · NA
-
More Individualized Care: Assessment and Recovery Through Engagement
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI